首页> 美国卫生研究院文献>Saudi Pharmaceutical Journal : SPJ >Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste
【2h】

Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste

机译:灰黄霉素的环糊精基纳米海绵作为儿童口服液剂型的配制和评估可增强生物利用度并掩盖苦味

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was the development of griseofulvin (GRI) loaded β-cyclodextrin (β–CD) based nanosponges for bitter taste masking, improving dissolution rate and oral bioavailability. Plain NS (NS1 NS2 and NS3) were fabricated by reacting β-CD with the cross-linker diphenyl carbonate at different molar ratios (1:2, 1:4 and 1:6, respectively) using ultrasonication method. The NS2 provided both highest %yield and GRI solubilization enhancement. Thus, the drug was loaded in NS2 at different NS2: drug weight ratios in presence or absence of 0.25%w/w polyvinylpyrolidone (PVP k30). The GRI loaded NS (F1) that provided highest drug loading capacity and entrapment efficiency (47.20   0.38%, 84.91 ± 0.30%, respectively) was morphologically examined using scanning electron microscopy (SEM). Also, Particle size, zeta potential, differential scanning calorimetry (DSC), Fourier transform infra-red (FT-IR), nuclear magnetic resonance (NMR) spectroscopy, release, taste masking potential were evaluated. Moreover, Pharmacokinetic studies were performed on rats. The F1 showed particle size 665.9 ± 13.8 nm and zeta potential −21.5 ± 0.7 mV. The DSC and FT-IR analysis confirmed the complexation of GRI with NS2. Nanosponges (F1) provided 3.19, folds increase in dissolution efficiency %, 2.13 and 3.78 folds increase in C and AUC compared to plain GRI. Taste masking evaluation confirmed the potential of GRI nanosponges (F1) in masking the bitter taste of GRI completely. The study confirmed that complexation of GRI with NS would be a viable approach for masking the bitter taste of GRI and improving oral bioavailability, that Cmax, Tmax and AUC 0–48 were significantly higher for the developed formulation (F1).
机译:这项研究的目的是开发基于灰黄霉素(GRI)的基于β-环糊精(β–CD)的纳米海绵,用于掩盖苦味,提高溶出度和口服生物利用度。通过使用超声方法使β-CD与交联剂碳酸二苯酯以不同的摩尔比(分别为1:2、1:4和1:6)反应来制备纯净NS(NS1 NS2和NS3)。 NS2提供了最高的%产率和GRI增溶作用。因此,在存在或不存在0.25%w / w聚乙烯吡咯烷酮(PVP k30)的情况下,将药物以不同的NS2:药物重量比加载到NS2中。使用扫描电子显微镜(SEM)在形态上检查了载有GRI的NS(F1),其提供了最高的载药量和包封效率(分别为47.20%,0.38%,84.91±0.30%)。此外,还评估了粒径,ζ电势,差示扫描量热法(DSC),傅立叶变换红外(FT-IR),核磁共振(NMR)光谱,释放,掩味电势。此外,在大鼠上进行了药代动力学研究。 F1的粒径为665.9±13.8 nm,ζ电位为-21.5±0.7 mV。 DSC和FT-IR分析证实了GRI与NS2的复合。与普通GRI相比,纳米海绵(F1)的溶解效率提高了3.19倍,C和AUC的溶解效率提高了2.13倍和3.78倍。掩味评估证实了GRI纳米海绵(F1)在完全掩盖GRI苦味方面的潜力。研究证实,GRI与NS的络合将是掩盖GRI苦味并改善口服生物利用度的可行方法,对于已开发的配方(F1),Cmax,Tmax和AUC 0-48明显更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号